Neurobehavioural Effects of Acute and Repeated Administrations of Sub-Psychotomimetic Dose of Ketamine in Mice
No Thumbnail Available
Date
2019
Journal Title
Journal ISSN
Volume Title
Publisher
Ife Journal of Science and Technology
Abstract
Recent studies have shown that sub-anaesthetic doses of ketamine may induce analgesia, but its psychotomimetic side effects have called for caution. This study therefore, explored a possible sub-psychotomimetic dose of ketamine (SPDK) and determined the influence of frequency of exposure on its neurobehavioural effects in mice. Mice of either sex weighing 18 - 25 g were randomly selected into three major groups: A, B, and C. Group A was distributed into seven sub-groups (n=12) and treated with saline (10 μL/g/body weight); 1, 2, 4, 6, 8, and 10 mg/kg ketamine for stereotyped horizontal locomotion (SHL) assessment using the open field test. Groups B and C were each allotted into three sub-groups (n=7): I, II, and III. They were treated with saline (10 μL/g/body weight) as negative control, 1 mg/kg ketamine and 1.5 mg/kg scopolamine as positive control; and assessed for neurobehavioural effects of acute and repeated administrations using elevated plus-maze (EPM) and Y-maze respectively. Data were presented as Mean ± SEM and analyzed using ANOVA followed by Student-Newman-Keuls test with p < 0.05. The results showed that 1 mg/kg ketamine is devoid of psychotomimetic side effects (1.979, p > 0.05), whereas, ketamine 2, 4, 6, 8 and 10 mg/kg induced significant increase (8.258, p < 0.001), (7.688, p < 0.001), (7.916, p < 0.001), (10.580, p < 0.001) and (13.244, p < 0.001) respectively in SHL compared with the saline group in the open field paradigm. Therefore, ketamine 1 mg/kg was chosen as the sub-psychotomimetic dose. Acute administration of SPDK did not significantly impair memory of mice in both EPM (6.751, p < 0.001) and Y-maze models (3.467, p < 0.05), whereas, its repeated administrations showed comparable results to the group administered scopolamine in both EPM (0.1460, p > 0.8654) and Y-maze models (1.258, p > 0.3126). This study concluded that 1 mg/kg of ketamine may be a sub-psychotomimetic dose; and ketamine-induced psychotomimetic side effects and cognitive impairments could be dose and time-dependent respectively.
Keywords: Neurobehavioural effects; sub-psychotomimetic dose of ketamine; drug re-positioning;
stereotyped horizontal locomotion; scopolamine
Description
Keywords
Research Subject Categories::PHARMACY::Pharmaceutical pharmacology